SLC6A19

Across TCGA pan-cancer cohorts, SLC6A19 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC6A19 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC6A19 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SLC6A19 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC and PDAC are the cancer types where SLC6A19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.926	0.759	.005	19	view →
PDAC	DFS	Median	All	0.488	0.230	.009	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SLC6A19–CCRCC (OS)

Open the CCRCC breakdown →